Europe Nuclear medicine Radiopharmaceuticals market – Market Data Forecast
Europe Nuclear Medicine Radiopharmaceuticals Market by Diagnostics (SPECT, PET), by Therapeutics (Beta Emitters, Alpha Emitters, Brachytherapy), by Application (cardiology, lymphoma, thyroid, neurology oncology) and by Region
(EMAILWIRE.COM, February 05, 2018 ) The Europe Nuclear medicine Radiopharmaceuticals Market is estimated at $1.04 Billion in 2015 and is expected to reach $1.78 billion by 2020, growing at a CAGR of 11.4%. Nuclear medicine falls under the field of Molecular imaging, which involves usage of minute amount of radioactive material (radiopharmaceuticals) to diagnose and treat disease.
View Full Report @ http://www.marketdataforecast.com/market-reports/europe-nuclear-medicine-radiopharmaceuticals-market-131/
Increasing prevalence of chronic diseases such as cancer and cardiac ailments, rapid technological advancements, increasing demand for SPECT and PET applications and the growing public awareness for healthcare are fuelling the market growth for Radiopharmaceuticals. Further, Integration of X ray tomography (CT) into SPECT has emerged as an excellent diagnostic tool in the medical imaging and is considered to be a driving factor for the growth of the market. Strict regulatory framework pose as a great hurdle to translational research & clinical investigations and reimbursement issues are blocking the growth of the market. In addition, shorter half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures are the key factors restraining the Europe nuclear medicine Radioisotopes market.
Download Free Sample Report @ http://www.marketdataforecast.com/market-reports/europe-nuclear-medicine-radiopharmaceuticals-market-131/request-sample
Market Segmentation
• By Type
o Diagnostic Radioisotopes
o SPECT
o PET
• Therapeutic Radioisotopes
o Beta Emitters
• By Application
o Cardiology
o Lymphoma
o Thyroid
o Neurology
o Oncology
o Others
Avail Discount @ http://www.marketdataforecast.com/market-reports/europe-nuclear-medicine-radiopharmaceuticals-market-131/request-discount
Radiopharmaceuticals market is dominated by diagnostic radioisotopes with a market share of 90 % while therapeutic radioisotopes contribute a minor share of around 10% of the market. Based on type of radioisotopes the market is segmented into Technetium-99m (TC-99m), Thallium-201 (TL-201), Fluorine-18,Iodine (I-123), Rubidium-82 (RB-82) and others. The F-18 market is mostly contributed by F-18 FDG tracers though this market is enriched with future tracers such as F-18 Florbetapir and F-18 Choline. The promising clinical outcomes of these tracers have been gaining the business interest of major research institutes and PET isotope players. Ga-68 and Rb-82 are two new potential isotopes in the PET diagnostic market, ensuring high growth of the diagnostics segment. Diagnosis of coronary artery disease, bone metastasis, and Alzheimer’s disease are the most promising indications for the future PET radioisotopes market.
Buy now @ https://www.marketdataforecast.com/cart/buy-now/europe-nuclear-medicine-radiopharmaceuticals-market-131
Some of the key players influencing the Europe nuclear medicine market are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation,Positron Corporation,Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
View Full Report @ http://www.marketdataforecast.com/market-reports/europe-nuclear-medicine-radiopharmaceuticals-market-131/
Increasing prevalence of chronic diseases such as cancer and cardiac ailments, rapid technological advancements, increasing demand for SPECT and PET applications and the growing public awareness for healthcare are fuelling the market growth for Radiopharmaceuticals. Further, Integration of X ray tomography (CT) into SPECT has emerged as an excellent diagnostic tool in the medical imaging and is considered to be a driving factor for the growth of the market. Strict regulatory framework pose as a great hurdle to translational research & clinical investigations and reimbursement issues are blocking the growth of the market. In addition, shorter half-life of radiopharmaceuticals and competition from orthodox diagnostic procedures are the key factors restraining the Europe nuclear medicine Radioisotopes market.
Download Free Sample Report @ http://www.marketdataforecast.com/market-reports/europe-nuclear-medicine-radiopharmaceuticals-market-131/request-sample
Market Segmentation
• By Type
o Diagnostic Radioisotopes
o SPECT
o PET
• Therapeutic Radioisotopes
o Beta Emitters
• By Application
o Cardiology
o Lymphoma
o Thyroid
o Neurology
o Oncology
o Others
Avail Discount @ http://www.marketdataforecast.com/market-reports/europe-nuclear-medicine-radiopharmaceuticals-market-131/request-discount
Radiopharmaceuticals market is dominated by diagnostic radioisotopes with a market share of 90 % while therapeutic radioisotopes contribute a minor share of around 10% of the market. Based on type of radioisotopes the market is segmented into Technetium-99m (TC-99m), Thallium-201 (TL-201), Fluorine-18,Iodine (I-123), Rubidium-82 (RB-82) and others. The F-18 market is mostly contributed by F-18 FDG tracers though this market is enriched with future tracers such as F-18 Florbetapir and F-18 Choline. The promising clinical outcomes of these tracers have been gaining the business interest of major research institutes and PET isotope players. Ga-68 and Rb-82 are two new potential isotopes in the PET diagnostic market, ensuring high growth of the diagnostics segment. Diagnosis of coronary artery disease, bone metastasis, and Alzheimer’s disease are the most promising indications for the future PET radioisotopes market.
Buy now @ https://www.marketdataforecast.com/cart/buy-now/europe-nuclear-medicine-radiopharmaceuticals-market-131
Some of the key players influencing the Europe nuclear medicine market are GE Healthcare, Hologic Inc., Medix Inc., Segami Corporation,Positron Corporation,Bracco Imaging S.p.A, Naviscan Inc., Bayer Healthcare, Lantheus Medical Imaging, Inc. and IBA Molecular Imaging.
About Market Data Forecast:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialities with competitive pricing options. For more info kindly visit, www.marketdataforecast.com
Contact Information:
Market Data Forecast
Abhishek Shukla
Tel: 1-888-702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Market Data Forecast
Abhishek Shukla
Tel: 1-888-702-9626
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results